<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00817440</url>
  </required_header>
  <id_info>
    <org_study_id>16.12.2008</org_study_id>
    <nct_id>NCT00817440</nct_id>
  </id_info>
  <brief_title>Effects of Fasting and Exercise on Insulin and GH Signaltransduction in Muscle and Fat</brief_title>
  <acronym>FEIGH</acronym>
  <official_title>Effects of Fasting and Exercise on Insulin and GH Signaltransduction in Muscle and Fat</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <brief_summary>
    <textblock>
      Hypothesis: under fasting there will primarily be an activation of growth hormone(GH)&#xD;
      signalpathways and a inhibition of insulin signalpathways, and the opposite will happen under&#xD;
      physical activity.&#xD;
&#xD;
      Primarily we will investigate markers for GH and insulin signaltransduction in muscle- and&#xD;
      fat-biopsies after fasting for 72 hours and after 1 hour of ergometer-cycling at 65% Vo2max.&#xD;
&#xD;
      In addition to this we will investigate the effect of fasting and exercise on the velocity of&#xD;
      carbamide synthesis, aminoacid rate of turnover and glucose rate of turnover.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Growth hormone and insulin signal pathways</measure>
    <time_frame>30 min</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>aminoacid and glucose turnover</measure>
    <time_frame>4 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>control: muscle and fat biopsies and basal aminoacid and glucose turnover</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exercise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 hour ergometer cycling on 65% of Vo2max, and then the same as arm 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fasting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 days of fasting and then the same as arm 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Exercise</intervention_name>
    <description>1 hour ergometer cycling on 65% of Vo2max, and then the same as arm 1.</description>
    <arm_group_label>Exercise</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fasting</intervention_name>
    <description>3 days of fasting and then the same as arm 1</description>
    <arm_group_label>Fasting</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  healthy men&#xD;
&#xD;
          -  Body mass index (BMI) 20-26&#xD;
&#xD;
          -  age 18-45 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  any kind of disease&#xD;
&#xD;
          -  any use of medicine&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Aarhus sygehus</name>
      <address>
        <city>Aarhus</city>
        <state>Jylland</state>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <study_first_submitted>January 5, 2009</study_first_submitted>
  <study_first_submitted_qc>January 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2009</study_first_posted>
  <last_update_submitted>January 10, 2011</last_update_submitted>
  <last_update_submitted_qc>January 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2011</last_update_posted>
  <responsible_party>
    <name_title>Mikkel Vendelbo MD</name_title>
    <organization>endokrinologiskforskningslaboratorium M, Aarhus sygehus</organization>
  </responsible_party>
  <keyword>growth hormone insulin signaltransduction signalpathways</keyword>
  <keyword>growth hormone and insulin signalpathways</keyword>
  <pending_results>
    <submitted>November 3, 2011</submitted>
    <returned>December 6, 2011</returned>
    <submitted>January 20, 2012</submitted>
    <returned>February 21, 2012</returned>
    <submitted>June 18, 2012</submitted>
    <returned>July 19, 2012</returned>
    <submitted>August 3, 2012</submitted>
    <returned>August 31, 2012</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

